SENTARA COMMUNITY PLAN (MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Drug Requested: Otezla® (apremilast)

MEMBER & PRESCRIBER INFORMA	ATION: Authorization may be delayed if incomplete.		
Member Name:			
Member Sentara #:			
Prescriber Name:			
	Signature: Date:		
Office Contact Name:			
one Number: Fax Number:			
DEA OR NPI #:			
DRUG INFORMATION: Authorization ma	ay be delayed if incomplete.		
Drug Form/Strength:			
Dosing Schedule:	Length of Therapy:		
Diagnosis:	ICD Code, if applicable:		
Weight:	Date:		
DIAGNOSIS	Recommended Dose		
□ Active Psoriatic Arthritis (PsA)	Titrate to recommended dose of 30 mg twice daily. 60 tablets every 30 days		
☐ Moderate to Severe Chronic Plaque Psoriasis - who are candidates for systemic therapy or phototherapy	Titrate to recommended dose of 30 mg twice daily. 60 tablets every 30 days		
☐ Oral Ulcers associated with Behcet's Disease	Titrate to recommended dose of 30 mg twice daily. 60 tablets every 30 days		

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

DIAGNOSES: Check the applicable diagnosis below or authorization will be denied.					
□ Active Psoriatic Arthritis (PsA)					
	Patient must have diagnosis of psoriatic arthritis.				
	AND				
	Medication <u>must</u> be prescribed by or in consultation with a rheumatologist or dermatologist				
	<u>AND</u>				
	Not receiving Otezla® in combination with a biologic DMARD [e.g., Enbrel® (etanercept), Humira®				
	(adalimumab), Simponi® (golimumab), Orencia® (abatacept)]				
	<u>AND</u>				
	Trial and failure of, contraindication, or adverse reaction to methotrexate				
	<u>AND</u>				
	Trial and failure of TWO (2) PREFERRED drugs below:				
	☐ Humira [®]	□ Enbrel [®]	□ Infliximab		
□ M	loderate to Severe Chronic	Plaque Psoriasis - who are ca	andidates for		
systemic therapy or phototherapy					
	Patient must have diagnosis of moderate to severe chronic plaque psoriasis				
	<u>AND</u>				
	Medication must be prescribed by or in consultation with a dermatologist				
	<u>AND</u>				
	Must have a previous failure on a topical psoriasis agent and be a candidate for phototherapy or systemic therapy				
	<u>AND</u>				
	Not receiving Otezla® in combination with a biologic DMARD [e.g., Enbrel ® (etanercept), Humira ®				
	(adalimumab), Simponi® (golimumab), Orencia® (abatacept)]				
	<u>AND</u>				
	Trial and failure of, contraindication, or adverse reaction to methotrexate				
	<u>AND</u>				

(Continued on next page

	☐ Trial and failure of TWO (2) PREFERRED drugs below				
	☐ Humira®	□ Enbrel®	☐ Infliximab		
□ Oral Ulcers associated with Behcet's Disease					
	☐ Medication <u>must</u> be prescribed by or in consultation with a rheumatologist or dermatologist				
	<u>AND</u>				
	☐ Member must have ulcers associated with Behcet's Disease				
Medication being provided by Specialty Pharmacy - PropriumRx					

Use of samples to initiate therapy does not meet step-edit/preauthorization criteria.

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *